Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · May 2013 · 1 min read
In brief
In brief
This preclinical study demonstrates that rapamycin achieves >95% tumor growth inhibition in a rhabdomyosarcoma xenograft model by simultaneously blocking mTOR and hedgehog signaling pathways. The dual pathway inhibition reduced proliferation markers, enhanced apoptosis, and decreased tumor invasiveness, suggesting a promising targeted therapy approach for metastatic and refractory RMS patients.
Written by the GCMD Library team from the article.
Statements in this article
Rhabdomyosarcomas represent the most common childhood soft-tissue sarcoma.
Patients with metastatic or relapsed rhabdomyosarcoma face a grim prognosis despite improvements in outcomes for low and intermediate risk patients.
New chemotherapeutic agents or combinations of chemotherapies have largely failed to improve outcomes in rhabdomyosarcoma.
The PI3K/AKT/mTOR pathway has been found to be a potentially attractive target in rhabdomyosarcoma therapy.
Rapamycin abrogates growth of rhabdomyosarcoma development in a xenograft mouse model.
More than 95% inhibition in tumor growth was observed in mice receiving parenteral administration of rapamycin compared to vehicle-treated controls.
Residual tumors in rapamycin-treated mice showed significant reduction in the expression of biomarkers indicative of proliferation and tumor invasiveness.
Tumors in rapamycin-treated mice showed enhanced apoptosis.
Rapamycin diminished rhabdomyosarcoma tumor growth through simultaneous inhibition of mTOR and hedgehog pathways.